The Chinese pharmaceuticals industry is growing rapidly as firms trade imitation for innovation, attracting talent and investors, notably in biotechnology.
This interview with Peter Krenander is the third in a series from #BoydenSweden exploring strengths, challenges, and passions as Managing Partner at Boyden Sweden.
The survey aims to understand the outlook around demand and availability of executive talent, global mobility, time to recruit, remuneration and a breakdown of growth potential by sector.
As their prevalence within the global healthcare logistics industry grows, medical drones could be clearing the way for drone deliveries of all kinds.
With the acquisition of biotech start-up Peloton Therapeutics, Merck will strengthen its portfolio as well as its position in oncology immunotherapy.
Lower volumes, higher biotech industry costs, and the departure of big pharmaceutical companies from the field thwart development of new antibiotics.
Continuing to execute on its new R&D strategy, GlaxoSmithKline has agreed to buy the rights to a next-generation cancer immunotherapy from Merck.
By merging with Celgene in a record $74 billion deal, Bristol-Meyers will create a formidable organization in the competitive immunotherapy space.
Takeda finally has approval to acquire another large firm, Ireland-based Shire, for $56 billion in the biggest-ever foreign takeover by a Japanese firm.
